Most Recent
Sandoz has accused Amgen of 'dragging the chain' as the Swiss biotech continues to mull whether to launch infringement proceedings over six patents for its Prolia and Xgeve bone disease biologics.
Generic drug maker Sandoz wants to shield information turned up by preliminary discovery orders from the eyes of Amgen patent attorneys in a spat over cheap versions of Amgen's bone disease drugs, and says if they view the material they should be barred from prosecuting future related patents.
Pharmacor will be allowed to sell a generic version of heart drug Entresto after the Full Court rejected Swiss drug giant Novartis' appeal of a ruling that found an extension of the term of its patent for the drug was invalidly granted.
Pharmaceutical giant Novartis is challenging the loss of its case against Sydney-based generics company Pharmacor over a patent for heart medication Entresto.
Swiss pharmaceutical giant Novartis has lost its patent infringement case against Sydney-based generics company Pharmacor over a top-selling heart medication.
Isuzu is not giving up its bid to slam the brakes on a suit by car alarm company Directed Electronics over alleged trade secrets theft.
Vehicle maker Isuzu can't shut down an $18 million suit by car alarm company Directed Electronics over a former employee’s alleged theft of trade secrets.
South Korean biotech ToolGen has won court approval to patent its genome editing technology CRISPR, after an earlier bid to protect its IP found the revolutionary technology was not patentable.
The maker of Mother energy drinks has won an appeal of an IP Australia decision, succeeding in its bid to prevent a Victoria-based company from registering Kangaroo Mother as a trade mark for beverages.